Stage 4 mesothelioma, also called late-stage or stage IV mesothelioma, is the most advanced mesothelioma stage: the cancer has spread beyond where it started to distant parts of the body, such as the bones, the opposite lung, the lining of the abdomen, or faraway lymph nodes. With treatment, median survival is about 12 to 18 months for pleural mesothelioma, the most common type. Peritoneal patients who qualify for surgery with heated chemotherapy (HIPEC) have reported medians of 30 months or more, though those studies include earlier stages, while pericardial mesothelioma has the shortest life expectancy, about 7 months. Because surgery rarely cures cancer this advanced, stage 4 treatment focuses on slowing the disease and keeping patients comfortable.
A stage 4 diagnosis can feel frightening, but it doesn’t mean care comes to an end. Mesothelioma life expectancy and prognosis figures are averages from large patient groups, and overall health, cell type, and access to specialized care all shape each person’s outlook. The survival table below lists sources and data years for each figure.
Median survival is the point at which half of patients in a study were still alive. These figures come from studies of advanced disease; few studies report stage 4 alone.
| Type | Median Survival (With Treatment) | Median Survival (Without Treatment) | Source / Data Year |
| Pleural, chemotherapy | 12–16 months | 4–12 months | Schumann et al., 2021 (citing 2003 trial); chemo arms of CheckMate 743 (2020) and KEYNOTE-483 (2024) |
| Pleural, Opdivo + Yervoy | 18 months | – | FDA, CheckMate 743, approved Oct. 2, 2020 |
| Pleural, Keytruda + chemotherapy | 17 months | – | ASCO Post, KEYNOTE-483, approved Sept. 17, 2024 |
| Peritoneal, CRS + HIPEC | 30–92 months across studies (all stages) | Under 5 to about 12 months | Kim et al., 2017 |
| Peritoneal, chemotherapy alone | 8–13 months | – | Kim et al., 2017 |
| Pericardial | About 7 months from diagnosis (all stages); treatment has limited effect | – | Systematic review, Cancers, 2026 |
These are group averages from past patients, not predictions for any one person. Your care team can tell you what they mean for your situation.
Stage 4 is the final and most advanced of the four mesothelioma stages. Doctors use the TNM system to stage malignant pleural mesothelioma: T describes the tumor’s size and how far it has grown, N describes whether cancer has reached nearby lymph nodes, and M describes whether it has spread to distant organs. Those three scores are combined into stages I through IV:
The key difference between stage 3 and stage 4 is distant spread:
| Stage 3 | Stage 4 | |
| Where the cancer is | Nearby structures and lymph nodes, including those on the opposite side of the chest or above the collarbone | Distant sites, such as the bones, the opposite lung or pleura, or the lining of the abdomen |
| TNM rule | No distant spread (M0) | Distant spread (M1), with any tumor size or lymph node status |
Source: American Cancer Society, using AJCC Version 9 staging.
The American Cancer Society and National Cancer Institute both note that systemic treatments such as chemotherapy and immunotherapy are still used at stage IV to slow the disease.
Peritoneal mesothelioma is staged with the peritoneal cancer index (PCI), which scores tumor spread across 13 regions of the abdomen from 0 to 39. A score of 31 to 39 is the most advanced category. Pericardial and testicular mesothelioma have no formal staging system because they are so rare.
A patient in stage 4 mesothelioma may experience more severe and persistent symptoms. You will likely want to seek information about what is causing your pain. A lot of mesothelioma diagnoses come in stage 3 or 4 because of the painful onset of symptoms.
Symptoms will vary based on where the cancer is located. Treatment options may be available to relieve symptoms and improve the patient’s quality of life. Oftentimes, treatment options may become more limited at stage 4, and patients turn to palliative care to manage their symptoms. Many of the symptoms in stage 4 are similar to those in other mesothelioma stages, but are typically more persistent.
At stage 4, mesothelioma symptoms are often more widespread because cancer cells may have reached distant organs and nearby lymph nodes. Mesothelioma patients sometimes find that symptoms that felt manageable during stage II or stage III become more difficult to control over time. Reporting any new or worsening symptoms to your care team as early as possible can help doctors, such as a mesothelioma specialist, adjust symptom management strategies before discomfort becomes more severe.
Possible symptoms may include:
Managing symptoms is a central part of care for mesothelioma in the final stages. While the disease itself may be advanced, many symptoms can still be treated or relieved, helping patients feel more comfortable and better able to manage daily life.
Common symptom-management options include:
If you or a loved one is experiencing symptoms, palliative care can help at any stage of mesothelioma, not just at the end of life. Palliative care focuses on comfort, symptom relief, and emotional well-being, and can be provided alongside active mesothelioma treatment.
Below is a table breaking down three first-line treatments that have been approved for advanced malignant pleural mesothelioma that can’t be removed with surgery, which includes stage 4:
| Treatment | Approved | Key Trial Result (Median Overall Survival) |
| Keytruda (pembrolizumab) + pemetrexed and platinum chemotherapy | Sept. 17, 2024 | 17 months vs. 16 months with chemotherapy alone (KEYNOTE-483) |
| Opdivo (nivolumab) + Yervoy (ipilimumab) | Oct. 2, 2020 | 18 months vs. 14 months with chemotherapy (CheckMate 743) |
| Pemetrexed (Alimta) + cisplatin or carboplatin | 2024 (pemetrexed) | 12 months vs. 9 months with cisplatin alone (2003 trial) |
Opdivo plus Yervoy is a chemotherapy-free immunotherapy combination. Keytruda adds immunotherapy to standard chemotherapy. Which option fits depends on cell type, overall health, and other factors your oncologist will weigh. Many patients also consider clinical trials of newer approaches.
Stage 4 mesothelioma life expectancy varies widely. The survival table above shows median survival by type and treatment option. Five-year figures tell a similar story: about 11% of people whose pleural mesothelioma had spread to distant sites lived at least five years, compared with 15% across all stages, according to the American Cancer Society (diagnoses from 2015 to 2021).
Several factors explain why outcomes differ so much among mesothelioma patients:
These numbers describe groups of patients diagnosed years ago, often before newer treatments were available. However, they can’t predict how any one person will do compared to another patient. That being said, the National Cancer Institute offers a plethora of information on mesothelioma cancer treatment and its various options.
Advanced pleural mesothelioma, which starts in the lining of the lungs, is the most common type, making up about 75% to 80% of cases. At stage 4, malignant pleural mesothelioma has spread beyond the chest to distant sites.
Chemotherapy with pemetrexed (Alimta) and cisplatin has long been the standard, with a median survival of about 12 months in its pivotal trial. Immunotherapy has added options: Opdivo plus Yervoy extended median survival to 18.1 months in CheckMate 743, and Keytruda plus chemotherapy reached 17.3 months in KEYNOTE-483.
Cell type matters as much as the mesothelioma type. Epithelioid mesothelioma, sometimes called epithelial mesothelioma, is the most common cell type and usually responds better to treatment. Sarcomatoid and biphasic mesothelioma cells tend to grow and spread faster, so these cancer cells are harder to control.
Some specialists combine treatments in a multimodal plan, such as systemic therapy with radiation to ease symptoms.
Peritoneal mesothelioma starts in the lining of the abdomen and makes up about 15% to 20% of cases. Peritoneal mesothelioma patients generally have a better outlook than those facing pleural mesothelioma.
The main treatment for eligible patients is cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC). Surgeons remove all visible tumor, then bathe the abdomen in heated chemotherapy to kill remaining cancer cells. Across studies, median survival after CRS and HIPEC ranges from 30 to 92 months, according to a 2017 review.
Doctors use the PCI score to judge how far the disease has spread and whether surgery makes sense. Higher scores mean more tumor and a harder operation. Among patients with the most extensive disease, about 29% lived five years after CRS and HIPEC in a 2011 multi-institution study. Not every patient qualifies, so an evaluation by a mesothelioma specialist at a mesothelioma center with HIPEC experience matters.
Stage 4 pericardial mesothelioma is extremely rare, accounting for just 1–2% of all mesothelioma cases. Because so few cases are diagnosed, available survival data is limited.
On average, survival is around 6 months, regardless of treatment. Pericardial mesothelioma affects the lining around the heart (pericardium) and is often diagnosed at an advanced stage, as symptoms can resemble other heart conditions. In some instances, the disease is not identified until after death.
By stage 4, the cancer often spreads within the chest and can interfere with normal heart function. Treatment options are limited due to the tumor’s location and late diagnosis, so care typically focuses on comfort and symptom relief, such as easing chest pain, reducing fluid buildup, and improving breathing, while supporting quality of life.
Because pericardial mesothelioma does not have a formal staging system, stage 4 is generally used when cancer spread has reached distant organs or extensively affected the heart. Most patients are treated at specialized mesothelioma centers, where cardiologists and oncologists work together to manage the unique challenges associated with this mesothelioma type.
Outcomes vary based on how much the heart is affected and the patient’s overall health at diagnosis.
Stage 4 testicular mesothelioma is the rarest form, accounting for less than 1% of cases. There is no formal staging system, and prognosis is assessed on a case-by-case basis.
It often presents earlier due to visible swelling or lumps. Stage 4 indicates spread to lymph nodes or distant organs. Treatment typically involves orchiectomy followed by chemotherapy. Some patients survive for several years, partly because they are of a younger age at diagnosis.
Although testicular mesothelioma is evaluated individually, the broader principles of cancer staging still apply. When the tumor has spread to lymph nodes or distant organs, it is generally considered stage 4 mesothelioma. Because the disease is so rare, most treatment knowledge comes from case reports and the wider mesothelioma cancer literature rather than large-scale clinical trials.
Age is one factor in stage 4 survival, but not the only one. In general, younger patients live longer. A study of national cancer registry data found that people 70 and older had about 2.5 times the risk of death of patients under 50, even after accounting for stage, treatment, and other factors (Enewold et al., 2017).
Still, overall health and fitness often matter more than age alone. An active 75-year-old with good heart and lung function may handle treatment better than a younger patient with other serious illnesses. Doctors measure this with a performance status score, which reflects how well someone manages daily activities.
Younger patients and older adults with advanced mesothelioma should both ask how their overall health, not just their age, shapes their treatment options.
A stage 4 mesothelioma prognosis reflects the overall outlook of the disease, not a fixed life expectancy. While statistics offer general guidance, prognosis varies widely based on how the cancer behaves and responds to treatment in each person.
The American Cancer Society and National Cancer Institute both emphasize that mesothelioma prognosis statistics are based on trends seen across large groups of mesothelioma patients and should not be viewed as individual predictions. For a stage 4 mesothelioma patient, prognosis is influenced by several factors, including the mesothelioma stage at diagnosis, mesothelioma type, and the extent of cancer spread to lymph nodes or distant organs.
At this stage, the cancer has spread beyond its original site, which limits curative options. That said, prognosis is not the same for everyone. Some patients respond well to treatment and live longer than expected, especially when cared for by specialists experienced in mesothelioma.
Access to specialized centers can make a meaningful difference. These teams often offer advanced treatments, including immunotherapy and clinical trials, and ongoing advances continue to improve outlooks for some stage 4 patients.
Several medical and personal factors influence mesothelioma stage 4 prognosis. Understanding these factors can help explain why outcomes vary so widely from one person to another.
Treatment for stage 4 mesothelioma focuses on slowing the disease, easing symptoms, and supporting quality of life, as the cancer has spread beyond its original location. While treatment is usually not curative, many options can still help patients feel better and live longer.
Clinical trials give some stage 4 patients access to newer treatments, including experimental CAR T-cell therapy, which reprograms a patient’s own immune cells to attack mesothelioma. A mesothelioma center can help you find trials you qualify for, and you can search current studies on ClinicalTrials.gov.
Because mesothelioma cancer is rare, not every oncologist has extensive experience diagnosing or treating malignant mesothelioma. Mesothelioma staging, mesothelioma cells, and the behavior of each mesothelioma type can differ significantly from other forms of cancer, which is why specialized care can play an important role in treatment planning.
A mesothelioma specialist is typically a thoracic oncologist, surgical oncologist, or physician with dedicated experience treating mesothelioma patients. These specialists may offer access to advanced mesothelioma treatment options that are not always available at general cancer centers, including HIPEC for Peritoneal Mesothelioma, multimodal treatment protocols for malignant pleural mesothelioma, and enrollment in clinical trials exploring newer therapies.
Many dedicated mesothelioma centers use multidisciplinary tumor boards to review each stage 4 mesothelioma case. These teams often include specialists in medical oncology, surgery, radiology, pulmonology, pathology, and palliative care who work together to develop individualized treatment recommendations.
The American Cancer Society encourages mesothelioma patients to consider seeking a second opinion at a center with dedicated mesothelioma expertise, especially when an initial mesothelioma diagnosis was made at a general hospital.
For many families, mesothelioma hope is closely tied to finding the right care team. While every situation is different, connecting with an experienced mesothelioma specialist and treatment center may help patients better understand their options and feel more supported throughout treatment.
Virtually all mesothelioma cancer cases, including stage 4 mesothelioma, are linked to past asbestos exposure. In many cases, that exposure happened decades before mesothelioma diagnosis, often in workplaces involving construction, shipbuilding, manufacturing, insulation, or military service.
One of the challenges with mesothelioma is its long latency period. Symptoms may not appear for 20–50 years after asbestos exposure occurs. Because mesothelioma symptoms can develop gradually and resemble more common illnesses, many mesothelioma patients are diagnosed at a later stage, including stage 4, after cancer spread has already progressed.
Lung cancer caused by asbestos exposure is a separate disease from mesothelioma, but both are considered asbestos-related diseases and share many of the same challenges associated with late-stage cancer diagnosis.
Some stage 4 mesothelioma patients and their families may also have legal options related to asbestos exposure, including compensation claims connected to past occupational or environmental exposure. Learning more about asbestos exposure and available legal compensation options may help families better understand the support that could be available to them.
Living with stage 4 mesothelioma may affect many areas of life, including physical health, emotional well-being, relationships, and daily routines. As symptoms change over time, patients may need increasing levels of support, both medically and practically.
For stage 4 mesothelioma patients and their families, maintaining a sense of purpose and connection alongside medical care can become an important part of living with late-stage mesothelioma. Many mesothelioma patients find that support from a comprehensive care team helps them better manage the physical and emotional demands of ongoing treatment while preserving comfort, independence, and quality of life.
Many people find it helpful to work with a coordinated mesothelioma care team that includes oncologists, palliative care specialists, nurses, social workers, and mental health professionals. This team-based approach can help address pain, breathing issues, fatigue, and emotional stress more effectively.
Support services can also help with practical concerns, such as transportation to appointments, managing medications, and navigating insurance or disability benefits. Patient advocacy organizations and community resources may provide additional guidance and connection.
A stage 4 diagnosis can make it difficult to absorb medical information, especially during early appointments. Preparing questions in advance can help make sure your concerns are addressed and that you understand your care plan.
In addition to asking about treatment options, many patients find it helpful to ask:
Bringing a trusted family member or friend to appointments, or requesting written summaries, can make these conversations easier to revisit later.
Coping with a stage 4 diagnosis is not purely a medical challenge; it is an emotional one. Feelings of fear, sadness, anger, and uncertainty are common, and these emotions may change over time.
Professional support can make a meaningful difference. Counselors, psychologists, or psychiatrists experienced in working with cancer patients can help manage anxiety or depression. Support groups, whether in person or online, allow patients to connect with others who understand what they are going through.
Caregivers also need support. Family members may experience stress, burnout, or emotional exhaustion, and counseling or caregiver-specific resources can help them cope while continuing to provide care.
At stage 4, maintaining quality of life is often the primary goal of care. While some aspects of the disease are beyond control, many others can be actively managed.
Small adjustments can make a meaningful difference. Pacing daily activities and accepting help when needed can help conserve energy. Working with a cancer nutritionist may improve strength and appetite, while gentle physical activity, such as short walks or stretching, can reduce fatigue and maintain mobility.
Many patients also explore complementary therapies such as acupuncture, massage, meditation, or music therapy to help manage stress and discomfort. These approaches can be used alongside medical treatment.
Importantly, quality of life also includes emotional and personal fulfillment. Spending time with loved ones, pursuing meaningful projects, or creating lasting memories can be an important part of living well with stage 4 mesothelioma.
For some people with mesothelioma, compensation can offer practical support and peace of mind. Financial recovery may help with treatment costs and daily expenses, while also providing a sense of accountability for past asbestos exposure. If you’d like to explore your options, our free guide or case evaluation can help you understand what support may be available.
Many stage 4 mesothelioma patients and their families have similar questions about filing compensation claims and understanding their legal options. Below are answers to a few of the most frequently asked questions.
Stage 4 mesothelioma is the most advanced mesothelioma stage. At this point, mesothelioma cancer has spread beyond the original tumor site to distant organs or nearby lymph nodes. Defined through the TNM cancer staging system, stage 4 mesothelioma is also commonly referred to as late-stage mesothelioma or stage IV mesothelioma.
Mesothelioma life expectancy at stage 4 varies depending on the mesothelioma type, overall health, treatment response, and mesothelioma cells involved. Stage 4 pleural mesothelioma averages approximately 12 months with treatment, while stage 4 peritoneal mesothelioma may reach around 26 months in some patients treated with CRS and HIPEC. Access to a mesothelioma specialist and specialized treatment can also influence mesothelioma survival rate outcomes.
Yes. Although curative surgery is rarely possible once cancer spread has reached distant organs, many stage 4 mesothelioma patients still receive mesothelioma treatment. Chemotherapy, immunotherapy, palliative care, and clinical trials may all play a role in treatment planning. A mesothelioma center with experience treating malignant mesothelioma can help identify the most appropriate options for each patient.
Stage 4 means the cancer has spread to distant parts of the body. Stage 3 cancer may have reached nearby structures and lymph nodes, but it hasn’t spread to distant sites. See the stage 3 vs. stage 4 comparison above.
Asbestos exposure is the primary cause of nearly all mesothelioma cancer cases. Because mesothelioma often develops decades after exposure, many mesothelioma patients are diagnosed at a later stage, including stage 4 mesothelioma, after symptoms appear and the cancer has already spread.
A stage 4 mesothelioma diagnosis does not mean facing everything alone. Whether you are exploring treatment options, trying to better understand mesothelioma prognosis, or researching support related to past asbestos exposure, help is available.
Connect with our team for a free case evaluation or download a free mesothelioma guide to learn more about treatment options, specialist care, and the resources that may be available to you and your family.
Our team of authors collaborates with the advocate team, focusing on writing about asbestos exposure and mesothelioma to spread awareness. They are dedicated to supporting families within the mesothelioma community.
American Cancer Society. “Malignant Mesothelioma.” https://www.cancer.org/cancer/types/malignant-mesothelioma.html
American Cancer Society. “Survival Rates for Mesothelioma.” Diagnoses 2015–2021. https://www.cancer.org/cancer/types/malignant-mesothelioma/detection-diagnosis-staging/survival-statistics.html
American Cancer Society. “Malignant Mesothelioma Stages.” Revised Feb. 3, 2026. https://www.cancer.org/cancer/types/malignant-mesothelioma/detection-diagnosis-staging/staging.html
National Cancer Institute. “Malignant Mesothelioma Treatment (PDQ)–Health Professional Version.” Updated May 12, 2025. https://www.cancer.gov/types/mesothelioma/hp/mesothelioma-treatment-pdq
National Cancer Institute. “Mesothelioma Treatment (PDQ)–Patient Version.” Updated May 16, 2025. https://www.cancer.gov/types/mesothelioma/patient/mesothelioma-treatment-pdq
Karpes, J. B., et al. (2023). “Malignant Peritoneal Mesothelioma: An In-Depth and Up-to-Date Review of Pathogenesis, Diagnosis, Management and Future Directions.” Cancers, 15(19), 4704. https://pmc.ncbi.nlm.nih.gov/articles/PMC10571654/
National Cancer Institute. “SEER Cancer Statistics.” https://seer.cancer.gov/statistics/
van Kooten, J. P., et al. (2022). “Incidence, Treatment and Survival of Malignant Pleural and Peritoneal Mesothelioma: A Population-Based Study.” Thorax. https://thorax.bmj.com/content/77/12/1260
U.S. National Library of Medicine. “Mesothelioma.” MedlinePlus. Updated Oct. 25, 2023. https://medlineplus.gov/mesothelioma.html
U.S. Food and Drug Administration. “FDA Approves Nivolumab and Ipilimumab for Unresectable Malignant Pleural Mesothelioma.” Oct. 2, 2020. https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-nivolumab-and-ipilimumab-unresectable-malignant-pleural-mesothelioma
The ASCO Post. “FDA Approves Pembrolizumab With Chemotherapy for Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma.” September 2024. https://ascopost.com/news/september-2024/fda-approves-pembrolizumab-with-chemotherapy-for-unresectable-advanced-or-metastatic-malignant-pleural-mesothelioma/
Schumann, S. O., Kocher, G., & Minervini, F. (2021). “Epidemiology, Diagnosis and Treatment of the Malignant Pleural Mesothelioma, a Narrative Review of Literature.” Journal of Thoracic Disease. https://pmc.ncbi.nlm.nih.gov/articles/PMC8107529/
Kim, J., Bhagwandin, S., & Labow, D. M. (2017). “Malignant Peritoneal Mesothelioma: A Review.” Annals of Translational Medicine, 5(11), 236. https://pmc.ncbi.nlm.nih.gov/articles/PMC5497105/
“Prognostic Factors and Survival in Pericardial Mesothelioma: A Systematic Review and Quantitative Analysis.” (2026). Cancers, 18(16), 2583. https://pmc.ncbi.nlm.nih.gov/articles/PMC13511537/
Enewold, L., Sharon, E., & Thomas, A. (2017). “Patterns of Care and Survival Among Patients with Malignant Mesothelioma in the United States.” Lung Cancer, 112, 102–108. https://pmc.ncbi.nlm.nih.gov/articles/PMC5726440/